Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Corcept Therapeutics (CORT)

Corcept President Sean Maduck to Retire Oct. 1; Justin Gunn Named Successor

Neutral Impact 3 of 5 leadership Written later

Corcept Therapeutics said Sean Maduck, President of its Endocrinology division, will retire effective October 1, 2026, and Justin Gunn will succeed him. Maduck will stay on as a consultant under an agreement paying $57,000 per month, and the company said he did not resign because of any disagreement with the company. The filing does not include financial results or guidance changes, so the direct effect on shareholders is limited to the leadership change.

Key points

  • Sean Maduck notified the board on September 22, 2026 of his decision to resign effective October 1, 2026.
  • Maduck's consulting agreement runs through September 30, 2027, with a cash fee of $57,000 per month, and his outstanding stock options continue to vest.
  • Justin Gunn joined Corcept in July 2024 as Vice President of Sales and Commercial Learning for the Oncology division and will report to CEO Joseph K. Belanoff, M.D.

The filing

CompanyCorcept Therapeutics (CORT)
Form8-K, current report
Filed with the SECSep 23, 2026, 8:15 AM ET
Accession number0001193125-26-398561

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 23, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.